Isis Lipid-Lowering Drug Shows Benefit In Phase II For Familial Hypercholesterolemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Isis 301012 shows treatment benefit as an add-on therapy to statins and other drugs.
You may also be interested in...
Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss
Firm revises net operating loss guidance downward by roughly $20 million.
Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss
Firm revises net operating loss guidance downward by roughly $20 million.
Isis Makes Quick Gain From Ortho-McNeil Pact, Enters Phase I For Novel Diabetes Candidate
Firm also will present positive Phase II data on novel small molecule targeting apolipoprotein B-100 for treatment of familial hypercholesterolemia later this week.